NetworkNewsBreaks – Brain Scientific Inc. (BRSF)
Post# of 129
(Total Views: 165)
Posted On: 04/19/2021 4:56:08 PM
NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Announces FY2020 Business, Financial Results
Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has released its 2020 financial results and has filed its annual report for the fiscal year ended Dec. 31, 2020. Company highlights include bringing the production of NeuroCaps(TM) to the United States; launching the commercial roll-out of its NeuroEEG(TM) and NeuroCap(TM) on a limited basis in the United States market; establishing wholly owned subsidiaries in Russia and Poland; and a significant increase in research and development efforts. Furthermore, the company announced that it has filed a provisional patent application for a new long-term monitoring EEG cap; in addition, its proprietary NeuroCap is now available in the U.S. pediatric market. Financial highlights include reported revenue of $544,275 for fiscal year 2020, compared to $489,202 for fiscal year 2019 with total company assets at the end of 2020 reaching $440,218 compared to $291,002 at the end of 2019. “In 2020, Brain Scientific made good progress toward our vision of introducing transformative brain diagnostic solutions that apply cutting-edge technologies and establish a new innovative norm for clinicians,” said Brain Scientific board chair Boris Goldstein in the press release. “We made strides on the operations front to improve lead times and quality control, as well as connections to expand our customer base in early 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has released its 2020 financial results and has filed its annual report for the fiscal year ended Dec. 31, 2020. Company highlights include bringing the production of NeuroCaps(TM) to the United States; launching the commercial roll-out of its NeuroEEG(TM) and NeuroCap(TM) on a limited basis in the United States market; establishing wholly owned subsidiaries in Russia and Poland; and a significant increase in research and development efforts. Furthermore, the company announced that it has filed a provisional patent application for a new long-term monitoring EEG cap; in addition, its proprietary NeuroCap is now available in the U.S. pediatric market. Financial highlights include reported revenue of $544,275 for fiscal year 2020, compared to $489,202 for fiscal year 2019 with total company assets at the end of 2020 reaching $440,218 compared to $291,002 at the end of 2019. “In 2020, Brain Scientific made good progress toward our vision of introducing transformative brain diagnostic solutions that apply cutting-edge technologies and establish a new innovative norm for clinicians,” said Brain Scientific board chair Boris Goldstein in the press release. “We made strides on the operations front to improve lead times and quality control, as well as connections to expand our customer base in early 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Brain Scientific, Inc. (BRSF) Stock Research Links
Scroll down for more posts ▼